The TRANSFORM Clinical Trial

Measuring the Prevention Potential of AI-Enabled Coronary CTA Analysis and Disease Staging

Webinar with Q&A – Watch Video

Can we prove that artificial intelligence (AI) works better to prevent heart disease progression than today’s decades-old approach?

In our eighth Transforming Cardiac Care webinar, we discussed the upcoming, landmark TRANSFORM randomized controlled trial that uses Cleerly’s AI-powered CCTA analysis. The study chair, Dr. Deepak L. Bhatt of Mount Sinai Fuster Heart Hospital, joined Cleerly’s clinical leaders to discuss and answer questions about the study’s goal of demonstrating that a highly personalized care strategy, empowered by AI identification of a patient’s coronary artery disease (CAD) stage, can outperform traditional risk factor management and even prevent cardiovascular events.

For more information on TRANSFORM, visit




Director, Mount Sinai Fuster Heart Hospital

In addition to his leadership at the top-ranked Mount Sinai Fuster Heart Hospital in New York City, Dr. Bhatt also serves as the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai. A renowned, award-winning expert and researcher in cardiovascular disease, Dr. Bhatt has authored over 2,000 articles and is the editor of the Journal of Invasive Cardiology and other publications.

James K. Min, MD

James K. Min, MD

Founder and Chief Executive Officer, Cleerly Inc.

Dr. Min is a globally recognized authority on cardiovascular imaging and physician scientist who understands the inter-relationships between non-invasive imaging, coronary angiography and revascularization.

James P. Earls, MD

James P. Earls, MD

Chief Medical Officer, Cleerly Inc.

Dr. Earls is a Professor of Radiology at George Washington University Hospital and a leader within the field of Radiology in applications of advanced imaging technologies in cardiovascular care.


Udo Hoffmann, MD, MPH

Chief Scientific Officer, Cleerly Inc.

Dr. Hoffmann is the former Professor of Radiology at Harvard Medical School and served as the Chief of the Division of Cardiovascular Imaging at the Department of Radiology at Massachusetts General Hospital (MGH). He was the Founding Director of the MGH Cardiovascular Imaging Research Center and was Principal Investigator of major National Institutes of Health (NIH)-supported clinical trials.


Our discussion covered multiple aspects of the TRANSFORM trial and the role of Cleerly’s AI-enabled CCTA software.


Learn about the trial’s geographic scope, patient participants, technologies, academic leaders, and partnerships.

Clinical Trial Hypothesis

Understand why and how the trial is testing personalized care based on the unique patient CAD stage versus traditional risk evaluation.

AI-enabled CCTA

Dive into the role of Cleerly’s technology in the trial and how it identifies patients’ unique stages of coronary artery disease.

Trial Outcomes and Benefits

Discussed potential results and the power of bringing together AI and the well-documented benefits of advanced heart disease medications to create individualized care plans and prevent cardiovascular events.

Webinar icon

The Cleerly webinars are open to any cardiologist, radiologist or other healthcare professional with an interest in breakthrough medtech for heart disease and prevention.